PTO/SB/05 (08-03)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to r

UTILITY PATENT APPLICATION **TRANSMITTAL**

(only for new nonprovisional applications under 37 CFR 1.53(b))

spond to a collection of info	rmation unless it displays a valid OMB control number
Attorney Docket No.	2057.0060002/JAG/BJD
First Inventor	Shyam S. BHASKARAN
Title	Polymer Conjugates of Cytokines
Express Mail Label No.	

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.					ADDRESS TO: Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450							
	⊠ ⊠	Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original, and a duplicate for fee processing) Applicant claims small entity status.	 CD-ROM or CD-R in duplicate, large table or Computer P (Appendix) Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) 									
3.	×	Specification [Total Pages 103] (preferred arrangement set forth below) Descriptive title of the Invention Cross Reference to Related Applications Statement Regarding Fed sponsored R & D Reference to sequence listing, a table, or a computer program listing appendix Background of the Invention Brief Summary of the Invention Brief Description of the Drawings (if filed)		a. 🔀 b. Sp	i. C ii. Z pa	Readable Form (CRF) quence Listing on: D-ROM or CD-R (2 of aper (6 pages) verifying identity of a MPANYING APP	copies); or	031356 U.S. PT 10/743295				
		- Detailed Description - Claim(s) - Abstract of the Disclosure	9.	\boxtimes	Assignment	Papers (cover sheet o	& document(s))					
4.	\boxtimes	Drawing(s) (35 U.S.C. 113) [Total Sheets 16]	10.		37 CFR 3.7 (when there i	3(b) Statement (s an assignee)	Power of Attorney					
5.	Oat	h or Declaration [Total Pages3_]	11.		English Tra	nslation Document (i)	fapplicable)					
		 a.	12.		Information Statement (Disclosure IDS)/PTO-1449	Copies of IDS Citations					
		(for continuation/divisional with Box 18 completed)	13.	13. Preliminary Amendment								
Signed statement attached deleting inventor(s)				14. Return Receipt Postcard (MPEP 503) (Should be specifically itemized)								
		named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).	 15. Certified Copy of Priority Document(s) (if foreign priority is claimed) 16. Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must atta form PTO/SB/35 or its equivalent. 									
6.	×	Application Data Sheet. See 37 CFR 1.76.										
		·	17.	\boxtimes	Other: A	uthorization under 37	C.F.R. § 1.136(a)(3)					
				Ø	_	he name of the assign harmaceuticals, Inc.	ee is: Mountain View					
18 or	. If	a CONTINUING APPLICATION, check appropriate box, and sup Application Data Sheet under 37 CFR 1.76:	ply th	ie reg	uisite informa	tion below and in a p	reliminary amendment,					
		Continuation Divisional Continuation-in-Part (CII)	P)	of 1	prior applicatio	on No:/ et Unit:						
CO	nsidei	NTINUATION OR DIVISIONAL APPS only: The entire disclosure of the red a part of the disclosure of the accompanying continuation or division dupon when a portion has been inadvertently omitted from the submitted	al anı	olicati	on and is here	which an oath or decl by incorporated by re	aration is supplied under ference. The incorporation	Box 5b, is on can only				
		19. CORRESPO	NDE	NCE	ADDRESS							
	X	Customer Number 26111				or Correspond	lence address below					
N.	NAME STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.											
		Attorneys at Law										
_	DDRI				 	· · · · · · · · · · · · · · · · · · ·						
_	ITY	STATE				ZIP CODE						
C	OUN	TRY TELEPHONE				FAX						
N.	АМЕ	(Print/Type) Brian J. Del Buono		Re	gistration No.	(Attorney/Agent) 42	2.473					

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Patent Application. Commissioner for Patents P.O. Box 1450. Alexandria VA 22313-1450. TO:: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

SIGNATURE

Date

DEC 23

PTO/SB/17 (08-03)
Approved for use through 07/31/2006. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no person

FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

Т	O	TAL	AMO	UNT	OF P	AYN	JEN1

(\$) 1932.00

		offection of information unless it displays a valid OMB control number				
	Complete if Known					
	Application Number	To be assigned				
	Filing Date	HEREWITH				
	First Named Inventor	Shyam S. BHASKARAN				
	Examiner Name	To be assigned				
	Art Unit	To be assigned				
	Attorney Docket No.	2057.0060002/JAG/BJD				

METHOD OF PAYMENT (check all that apply)	FEE CALCULATION (continued)								
☐ Check ☑ Credit card ☐ Money Order ☒ Other** ☐ None		3. ADDITIONAL FEES							
☐ Check ☒ Credit card ☐ Money Order ☒ Other** ☐ None ** Charge any deficiencies or credit any overpayments in the fees or fee calculations of Parts 1, 2 and 3 below to Deposit Account No. 19-0036.	<u>Large</u>	Entity	Sm	all En	tity				
Deposit Account Deposit Account Number 19-0036		Fee Fee (\$) Co	Fee de (\$)		Fee Description			Fee Paid	
Deposit Account Name: Sterne, Kessler, Goldstein & Fox P.L.L.C.	1051	130	2051	65	Surcharge - late filing	fee or oath			
The Commissioner is authorized to: (check all that apply)	1502	50	2052	25	Surcharge-late provisi sheet	ional filing fee	or cover		
☐ Charge fee(s) indicated below ☐ Credit any over payments	1053	130	1053	130	Non-English specificat	tion		 	
Charge any additional fee(s) during the pendency of this application	1812	2,520	1812	2,520	For filing a request for	ex parte ree	xamination	\vdash	
Charge fee(s) indicated below, except for the filing fee to the	1804	920*	1804	920*	Requesting publication action	n of SIR prior	to Examine		
above-identified deposit account.	1805	1,840*	1805	1,840*		n of SIR after	Examiner		
	1251	110	2251	55	Extension for reply wit	thin first mont	th		
	1252	420	2252	210	Extension for reply wit	hin second n	nonth	\vdash	
FEE CALCULATION	1253	950	2253	475	Extension for reply wit	thin third mon	ith	\vdash	
1. BASIC FILING FEE	1254	1,480	2254	740	Extension for reply wit	thin fourth mo	onth		
Large Entity Small Entity	1255	2,010	2255	1,005	Extension for reply wit	hin fifth mont	h		
Fee Fee Fee Fee Paid	1401	330	2401	165	Notice of Appeal				
Code (\$) Code (\$) 1001 770 2001 385 Utility filing fee 385.00	1402	330	2402	165	Filing a brief in suppor	t of an appea	al		
1002 340 2002 170 Design filing fee	1403	290	2403	145	Request for oral hearing	Request for oral hearing			
1003 530 2003 265 Plant filing fee	1451	1,510	1451	1,510	Petition to institute a p	ublic use pro	ceeding		
1004 770 2004 385 Reissue filing fee	1452	110	2452	55	Petition to revive - una	avoidable			
1105 160 2005 80 Provisional filing fee	1453	1,330	2453	665	Petition to revive - unit	ntentional			
SUBTOTAL (1) (\$)385.00	1501	1,330	2501	665	Utility issue fee (or reis				
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1502	480	2502	240	Design issue fee			<u> </u>	
Fee from Extra below Fee Paid	1503	640	2503	320	Plant issue fee				
Total Claims 171 - 20** = 151 X 9.00 = 1359.00	1460	130	1460	130	Petitions to the Commissioner				
Indep. Claims 4 - 3** = 1 X 43.00 = 43.00									
Multiple Dependent145.00_ =145.00	1807	50	1807	50	Processing fee under				
Large Entity Small Entity	1806	180	1806	180	Submission of Informa	ition Disclosu	re Stmt		
Fee Fee Fee Fee Fee Fee Description Code (\$)	8021	40	8021	40	Recording each patent property (times number	t assignment	per		
1202 18 2202 9 Claims in excess of 20	1809	770	2809	385	Filing a submission aff				
1201 86 2201 43 Independent claims in excess of 3 1203 290 2203 145 Multiple dependent claim, if not paid	1810	770	2810	385	1.129(a)) For each additional in	ention to be	ovominad		
1204 86 2204 43 **Reissue independent claims					For each additional inv (37 CFR 1.129(b))				
over original patent	1801	770	2801	385	Request for Continued	Examination	(RCE)		
1205 18 2205 9 **Reissue claims in excess of 20	1802	900	1802	900	Request for expedited application	examination	of a design		
and over original patent		Other fee (specify)							
SUBTOTAL (2) (\$) 1547.00 **or number previously paid, if greater; For Reissue, see above		iced by I		Filina F	ee Paid	SUBTOTAL	. (3) (\$)		
SUBMITTED BY	Regist	ration No				Complete (if			
Name (Print/Type) Brian J. Del Buono		ey/Agen			42,473	Telephone	202-371	-2600	
Signature WARNING: Information on this formation		=	>			Date	Dea	23, 2003	

I WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Traderrark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need excitators is accounted to the complete of the comple

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

BHASKARAN et al.

Appl. No.: To be assigned

Filed: HEREWITH

For: Polymer Conjugates of Cytokines,

Chemokines, Growth Factors,
Polypeptide Hormones and
Antagonists Thereof with
Preserved Receptor-Binding

Activity

Confirmation No.: To be assigned

Art Unit: To be assigned

Examiner: To be assigned

Atty. Docket: 2057.0060002/JAG/BJD

Authorization To Treat A Reply As Incorporating An Extension Of Time Under 37 C.F.R. § 1.136(a)(3)

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

The U.S. Patent and Trademark Office is hereby authorized to treat any concurrent or future reply that requires a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. The U.S. Patent and Trademark Office is hereby authorized to charge all required extension of time fees to our Deposit Account No. 19-0036, if such fees are not otherwise provided for in such reply.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Brian J. Del Buono Attorney for Applicants Registration No. 42,473

Date: 1003

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600 (202) (2

SKGF 1/25/02 mac; 4/18/03 svb



Robert Greene Sterne Edward J. Kessler Jorge A. Goldstein David K.S. Comwell David K.S. Comwell Robert W. Esmond Tracy-Gene G. Durkin Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee Michael Q. Lee Steven R. Ludwig John M. Covert Linda E. Alcom Robert C. Millonig Lawrence B. Bugaisky Donald J. Featherstone Michael V. Messinger Judith U. Kim Timothy J. Shea, Jr. Patrick E. Garrett Heidi L. Kraus Edward W. Yee Albert L. Ferro* Donald R. Banowit Peter A. Jackman Molly A. McCall Teresa U. Medler Jeffrey S. Weaver Kendrick P. Patterson Vincent L. Capuano Eldora Ellison Floyd Thomas C. Fiala Brian J. Del Buono Virnil Lee Reaston Virgil Lee Beaston Kimberly N. Reddick

Theodore A. Wood Elizabeth J. Haanes Bruce E. Chalker Joseph S. Ostroff Frank R. Cottingham Christine M. Lhulier Rae Lynn Prengaman Jane Shershenovich Lawrence J. Carroll* George S. Bardmesser Daniel A. Klein* Daniel A. Klein*
Jason D. Eisenberg
Michael D. Specht
Andrea J. Kamage
Tracy L. Muller*
Jon E. Wright*
LuAnne M. Yuricek*
John J. Eiguerna John J. Figueroa

Ann E. Summerfield Tiera S. Coston* Aric W. Ledford* Registered Patent Agents •

1

Karen R. Markowicz Nancy J. Leith Helene C. Carlson Gaby L. Longsworth Matthew J. Dowd Aaron L. Schwartz Mary B. Tung Katrina Y. Pei Quach Bryan L. Skelton Robert A. Schwartzman Timothy A. Doyle Jennifer R. Mahalingappa Teresa A. Colella Jeffrey S. Lundgren Victoria S. Rutherford Eric D. Hayes

<u>Of Counsel</u> Kenneth C. Bass III Evan R. Smith

*Admitted only in Maryland *Admitted only in Virginia •Practice Limited to Federal Agencies

December 23, 2003

WRITER'S DIRECT NUMBER: (202) 772-8525 **INTERNET ADDRESS:** BRIAND@SKGF.COM

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450 Mail Stop Patent Application

Re:

U.S. Non-Provisional Utility Patent Application under 37 C.F.R. § 1.53(b)

Appl. No.: To be assigned; Filed: HEREWITH

For:

Polymer Conjugates of Cytokines, Chemokines, Growth Factors, Polypeptide Hormones and Antagonists Thereof with Preserved

Receptor-Binding Activity

Inventors:

Shyam S. BHASKARAN, Merry R. SHERMAN, Mark G.P.

SAIFER and L. David WILLIAMS

Our Ref:

2057.0060002/JAG/BJD

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

- PTO Utility Patent Application Transmittal (Form PTO/SB/05); 1.
- 2. Form PTO-2038 Credit Card Payment Form in the amount of \$1932.00 to cover the appropriate filing fees;
- 3. PTO Fee Transmittal (PTO/SB/17);
- 4. Authorization to Treat a Reply As Incorporating An Extension of Time Under 37 C.F.R. § 1.136(a)(3);
- 5. U.S. Utility Patent Application entitled:

Sterne, Kessler, Goldstein & Fox PLLC.: 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 f 202.371.2540: www.skgf.com

Polymer Conjugates of Cytokines, Chemokines, Growth Factors, Polypeptide Hormones and Antagonists Thereof with Preserved Receptor-Binding Activity

and naming as inventors:

Shyam S. BHASKARAN Merry R. SHERMAN Mark G.P. SAIFER L. David WILLIAMS

the application consisting of:

- a. An Application Data Sheet (37 C.F.R. § 1.76);
- b. A specification containing a total of 103 pages:
 - i. 81 pages of description prior to the claims;
 - ii. 21 pages of claims (164 claims);
 - iii. a one (1) page abstract;
- c. 16 sheets of drawings: (Figures 1a, 1b, 1c, 1d and 2-13);
- d. 6 pages of a paper copy of a sequence listing; and
- e. An original executed Declaration;
- 6. Recordation Form Cover Sheet;
- 7. Form PTO-2038 Credit Card Payment Form in the amount of \$40.00 to cover the recordation fee;
- 8. An original executed Assignment to Mountain View Pharmaceuticals, Inc., recordation of which is hereby respectfully requested;
- 9. A computer readable copy of the sequence listing; and
- 10. Two (2) return postcards.

Commissioner for Patents December 23, 2003 Page 3

In accordance with 37 C.F.R. § 1.821(f), the paper copy of the sequence listing and the computer readable copy of the sequence listing submitted herewith in the above application are the same.

It is respectfully requested that, of the two attached postcards, one be stamped with the filing date of these documents and returned to our courier, and the other, prepaid postcard, be stamped with the filing date and unofficial application number and returned as soon as possible. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Brian J. Del Buono Attorney for Applicants Registration No. 42,473

BJD/nef Enclosures

::ODMA\MHODMA\SKGF_DC1;212810;1 SKGF Rev. 2/12/02 dcw; 9/5/02 mac; 4/29/03 svb